> ## Content Index
> Fetch the complete content index at: https://nexi.fund/llms.txt
> Use this file to discover other available public pages before exploring further.

# Contraline raises $92.5M to build the first reversible male contraceptive market
- URL: https://nexi.fund/contraline-reversible-male-contraception-2026/
- Published: 2026-08-07T15:30:18.000Z
- Updated: 2026-08-07T15:30:18.000Z
- Description: Contraline raised a $92.5M Series B to fund NES/T, a once-daily hormonal gel, through Phase 3 and advance ADAM, a non-hormonal implant, toward the first reversible male contraceptive product. It weighs a funded pipeline against the acceptance gap that sank earlier programs.
- Author: Nexi.fund Labs
- Tags: Biotech & Health, #mode-1, #hook-number, #track-E

For decades a man choosing contraception has had two options: a condom or a vasectomy. One is temporary and imperfect, the other permanent by design. No new male method has reached the market in a generation, and the category has quietly settled for that. In June a small biotech company closed a $92.5 million Series B on a different premise: that the missing product was never the biology, only the willingness to fund it.

Contraline, a clinical-stage biopharma based in Charlottesville, Virginia, is now carrying two candidates into late-stage development. One is a once-daily hormonal gel. The other is a non-hormonal implant. The round was co-led by two crossover funds that rarely back single-project companies, which makes the thesis worth reading carefully.

🎯

The $92.5 million Series B, co-led by BVF Partners and RA Capital with GV, Lumira Ventures and Invus, funds a Phase 3 plan for NES/T, a hormonal gel that already completed a 462-couple Phase 2b study.  
  
The second asset, ADAM, is a non-hormonal hydrogel implant for men who will not commit to a daily habit, giving the company two independent routes in a category with no approved product.  
  
The real open question is not whether sperm suppression works. It is whether men will keep using a product long enough, at scale, without an unacceptable side-effect profile. That acceptance gap killed the previous generation of hormonal methods. 

$92.5M Series B, announced June 2026 

#### Series B to fund male contraception

Closed by BVF Partners and RA Capital, with Google Ventures, Lumira Ventures and Invus among the participants. · *BioSpace, 2026*

## A category that never got built

Male contraception is not a small market because of weak demand. It is small because it has almost nothing to sell. The global male contraceptives market is valued at around $1.12 billion, a figure that stays low only because the available product mix is so thin. When the alternatives are condoms and vasectomy, the addressable population for something reversible and reliable has nowhere to go.

The field does not lack working mechanisms. Hormonal approaches have suppressed sperm for decades. What they kept failing on was how men were asked to participate. Earlier injectable programs reached high suppression rates, then halted over side effects such as mood changes, acne and injection-site pain. The pattern repeated often enough that the category went quiet for a generation. Scientists never stopped believing suppression worked. Investors stopped believing men would accept the cost of it.

#### Why earlier hormonal routes stalled

A progestin alone suppresses sperm but also suppresses testosterone, bringing side effects that were never tolerated at scale. The trials that did reach the clinic were frequently ended early on tolerability, not efficacy.  
  
NES/T attacks that specific failure: it pairs a synthetic progestin, segesterone acetate, with testosterone, so suppression happens without the low-testosterone problems that sank earlier programs. 

## Two products for two kinds of man

The lead asset is NES/T, a once-daily topical gel combining segesterone acetate (Nestorone) with testosterone. It is designed to suppress sperm production while holding serum testosterone in a normal range. The program recently completed a global Phase 2b study of 462 couples, and the company reports encouraging efficacy, tolerability, reversibility and user acceptability. Phase 3 is planned for 2027.

> Male contraception represents one of the largest unmet needs in reproductive health.— Kevin Eisenfrats, Co-founder and CEO, Contraline

The second product exists for the man who will not apply a gel daily. ADAM is a non-hormonal hydrogel placed into the vas deferens during an outpatient procedure. It blocks sperm mechanically, is reversible, and avoids hormones entirely. In the first-in-human study, the first participants to reach the 24-month mark reached azoospermia, the complete absence of sperm, from baselines above 80 million sperm per milliliter. The 30-participant study reported no serious adverse events. ADAM has since advanced into a Phase 2 trial.

## The investors behind the argument

The identity of the check-writers is the more interesting signal. BVF Partners and RA Capital are crossover funds that mostly back products, not category theses. Their participation frames male contraception as an addressable pharmaceutical market rather than a research project. The funding also resolved the question the field had quietly struggled with for years: how to pay for a Phase 3 when the largest drugmakers decline to touch the space.

> Contraline is helping redefine what reproductive choice can look like by giving men a more active role in family planning and expanding options for couples who may not be well served by existing contraceptives.— Laura Stoppel, Partner, RA Capital Management

Contraline holds the exclusive rights to the NES/T program, which was originally developed by the Population Council in collaboration with the National Institute of Child Health and Human Development at the National Institutes of Health. The intellectual property comes with institutional history rather than a blank slate. Eisenfrats has said the proceeds are enough to fund the entire Phase 3 through a potential submission with the FDA, a level of runway that most clinical-stage companies in this category never had.

## The acceptance hurdle is the honest core

Stripped of the funding story, the scientific question has been answered for years. Sperm can be suppressed. What has never been proven is that a meaningful number of men will maintain a daily or repeated habit without unacceptable side effects. The previous generation of hormonal programs died on exactly that point, and no Phase 2b dataset fully closes it. Adherence data from a large Phase 3 will be the first real test.

The market math, if it works, writes itself. Contraline cites survey data suggesting a meaningful share of American men would consider a novel method. A category currently served by condoms and surgery, valued at roughly $1.12 billion, moves from a small niche to a sizable market the moment a reversible product with acceptable tolerability exists. That is the trade the crossover investors bought into.

### By 2029, does a man have a real third option?

🔮

**The most likely path is an NES/T submission toward the late 2020s, not a category revolution by 2029.**  
  
Probability: 60%. A funded Phase 3 and a completed Phase 2b make a filing credible, but daily acceptance at scale remains the unproven variable. 

#### ✅ Arguments for

**1.** Phase 2b completed with tolerability and acceptability intact across 462 couples.  
**2.** Phase 3 is funded through a likely FDA submission, removing the field's historical funding bottleneck.  
**3.** Two independent mechanisms de-risk the franchise.  
  
**Confirmation criteria:** a completed Phase 3 that meets its suppression endpoint and reaches a filing. 

#### ❌ Arguments against

**1.** A daily habit is the historic failure mode of this exact category.  
**2.** A Phase 3 can consume two or more years even with funding in hand.  
**3.** Regulators will demand real-world acceptance data for a product without precedent.  
  
**Disconfirmation criteria:** a Phase 3 miss on efficacy or tolerability that blocks a label. 

## Development scenarios

#### 🟢 Optimistic scenario (30%)

**Approval and a real category.** NES/T clears Phase 3 and reaches the market before 2030, acceptance holds at scale, and the male contraception market expands into the addressable population it was always missing.  
  
**Implications:** a genuinely new market and a company built to lead it. 

#### 🟡 Base-case scenario (60%)

**Approval in the late 2020s, slower category build.** NES/T files and gains approval toward 2030, ADAM follows behind, and the category grows gradually rather than overnight.  
  
**Implications:** the first approved product for men, with measured rather than explosive upside. 

#### 🔴 Pessimistic scenario (10%)

**The acceptance gap closes the project.** A Phase 3 reveals a tolerability flaw, timelines stretch, and the category reverts to condoms and vasectomy.  
  
**Implications:** a long, expensive lesson about why the shelf has stayed empty. 

📊

**Key signals to track**  
  
Phase 3 timing and enrollment for NES/T through 2027  
  
Any regulatory position on a reversible product for men  
  
A rival route reaching late-stage trials, from pills to implants  
  
Whether crossover investors stay for the next round 

The argument is that an empty shelf is not the same as an empty market. Contraline has the first funded Phase 3 in a category that has not delivered a product in a generation. Whether men will accept what it builds is the question the market gets to answer next.

[ Contraline Announces $92.5 Million Series B Financing to Advance NES/T Male Contraceptive The funding details, the 462-couple Phase 2b result, and the funding path to an FDA submission. BioSpace ](https://www.biospace.com/press-releases/contraline-announces-92-5-million-series-b-financing-to-advance-nes-t-male-contraceptive-into-late-stage-development?ref=nexi.fund) 

Authoritative source for the round, the Phase 2b data and the Phase 3 plan.

[ Contraline secures $92.5m to push male contraceptive into late-stage trials Context on the first-to-market position in a category with no recently approved product. Pharmaceutical Technology ](https://www.pharmaceutical-technology.com/news/contraline-series-b-male-contraceptive/?ref=nexi.fund) 

Frames the competitive position.

[ Why Contraline's $92.5M raise could reshape the category Market sizing and the split between the hormonal gel, non-hormonal implant and oral routes. Life Science Intelligence ](https://www.lifesciencemarketresearch.com/insights/male-contraceptives-why-contralines-925m-raise-could-reshape-the-category?ref=nexi.fund) 

Market and route comparison.

[ Contraline secures $92.5M to push its male birth control candidates forward CEO interview covering the NES/T and ADAM portfolio and the Phase 2b-to-Phase 3 plan. MedCity News ](https://medcitynews.com/2026/06/contraline-birth-control-contraceptive-funding/?ref=nexi.fund) 

The portfolio framing.